Drug Discovery & Pharmaceuticals

RSS

UK scientists 3D-print the first human corneas

For the first time in history, scientists from have 3D-printed human corneas, providing a potential solution to the current shortage of corneas for transplant.

1 Jun 2018

Discovering Antibodies with Universal Specificity

Professor Hedda Wardemann discusses our current knowledge of antibody specificity and how her research team are challenging this, through the discovery of anti-bacterial antibodies with universal specificity.

1 Jun 2018

Study shows blood stem cells compensate for immune cell deficiencies

Researchers have shown that if certain blood stem cells that produce immune cells are deficient, other blood stem cells compensate by overproducing the immune cells that are lacking.

30 May 2018

Researchers uncover the cause of rheumatoid arthritis

A team of researchers have identified the cellular network involved in initiating and maintaining chronic inflammation in rheumatoid arthritis.

30 May 2018

Researchers identify novel target for bladder cancer

Researchers have identified an olfactory receptor in the human bladder that could prove useful in the diagnosis and treatment of bladder cancer.

29 May 2018

Novoheart announces next generation of 'Human heart-in-a-jar' technology for advanced drug discovery

Novoheart today announced that the next generation of its ‘Human heart-in-a-jar’ technology - which makes up a key component of its comprehensive MyHeartTM Platform - will be unveiled for the first time at the Annual Meeting of the International Society for Stem Cell Research, held in Melbourne, Australia from 20-23 June, 2018.

26 May 2018

Mapping the Genes Responsible for Pluripotency

Dr. Atilgan Yilmaz and his team have developed a method by which they can produce haploid human embryonic stem cells from oocytes. They combined this technique with CRISPR-Cas9 to generate an atlas of the genome, containing the functions of over 18,000 genes.

23 May 2018

DNA vaccine shows promise for colorectal cancer

For the first time in humans, researchers are testing a combined approach to treating advanced stage colorectal cancer (CRC) that may be life-changing for patients.

22 May 2018

Novel drug prevents memory impairment in mice exposed to simulated deep space radiation

Planning a trip to Mars? You'll want to remember your anti-radiation pills. NASA and private space companies like SpaceX plan to send humans to the red planet within the next 15 years--but among the major challenges facing future crewed space missions is how to protect astronauts from the dangerous cosmic radiation of deep space.

22 May 2018

Developing a High Throughput Mass Spectrometry Platform for Drug Discovery

Prof. Jonathan Wingfield, AstraZeneca, describes the collaboration with Labcyte and Waters to develop a high throughput mass spectrometry platform.

From Pittcon 18 May 2018

AstraZeneca collaborates with Emulate to integrate Organs-on-Chips technology into drug development labs

Emulate, Inc. has formed a collaborative partnership with AstraZeneca’s Innovative Medicines and Early Development Biotech Unit to embed its Organs-on-Chips technology within the laboratories of the IMED Drug Safety organization.

From AstraZeneca 17 May 2018

FutureNeuro and GreenLight Medicines team up to develop cannabis-based treatments for epilepsies

A new partnership between FutureNeuro, the SFI Research Centre for Chronic and Rare Neurological diseases based at RCSI and GreenLight Medicines, an indigenous Irish biopharmaceutical company has been formed to develop new cannabis-based treatments for drug-resistant epilepsies, and in particular, childhood epilepsies.

17 May 2018

Scientists uncover new target for MRSA

Researchers at Michigan State University have identified why methicillin-resistant Staphylococcus aureus or MRSA is so resilient, a finding that could pave the way for potential new treatments.

15 May 2018

Researchers use spheroids to screen for potential cancer drugs

Researchers from The Scripps Research Institute have reported a new and more effective way of screening for potential cancer drugs.

14 May 2018

Research may pave way for new C. diff antitoxins and anti-cancer drugs

Researchers from the University of California, Irvine and Harvard University have discovered how the Clostridium difficile toxin B recognizes the human Frizzled protein, the receptor it uses to invade intestinal cells and lead to deadly gastrointestinal infections.

14 May 2018

New tool provides high accuracy and precision in analyzing disease and drug effects

A new protein analysis tool developed at the University at Buffalo could vastly increase the speed and precision with which disease and drug effects are analyzed.

11 May 2018

New model based on combination of GANs with reinforcement learning for drug discovery

Insilico Medicine, a Baltimore-based next-generation artificial intelligence company specializing in the application of deep learning for target identification, drug discovery and aging research announces the publication of a new research paper in Molecular Pharmaceutics journal titled "Adversarial Threshold Neural Computer for Molecular De Novo Design".

10 May 2018

Penn engineers develop faster way to make drug microparticles

Pharmaceuticals owe their effects mostly to their chemical composition, but the packaging of these drugs into specific physical formulations also need to be done to exact specifications.

9 May 2018

OU researchers receive $5.7 million NIH grant to accelerate antibiotic discovery

University of Oklahoma professors, Helen Zgurskaya and Valentin Rybenkov, and team are addressing the challenge and critical need for new antibiotics that can fight infections caused by the multi-drug resistant bacterium, Pseudomonas aeruginosa, considered an urgent threat by the Centers for Disease Control and Prevention.

7 May 2018

Fujitsu announces development of molecular simulation technology for drug discovery

Fujitsu Laboratories Ltd. and Fujitsu Limited today announced the development of molecular simulation technology for drug discovery that can accurately estimate binding affinity, which represents the degree to which proteins that can cause diseases (target proteins) bind to chemical substances that could become candidate drugs.